Aberrant CpG island methylation in neurofibromas and neurofibrosarcomas

Oncology Reports

Volumn 10, Issue 5, 2003, Pages 1519-1523

  Gonzalez Gomez, Pilar ^a   Bello, M Josefa ^a   Arjona, Dolores ^a   Alonso, M Eva ^a   Lomas, Jesus ^a   De Campos, Jose M ^b   Kusak, M Elena ^b   Gutierrez, Manuel ^a   Sarasa, Jose L ^c   Rey, Juan A ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^c Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

CpG island methylation; Malignant peripheral nerve sheath tumour; MGMT; Neurofibroma; Neurofibromatosis; Neurofibrosarcoma; NF1; RB1; THBS1; TIMP 3

Indexed keywords

ADULT; ARTICLE; CENTRAL NERVOUS SYSTEM TUMOR; CPG ISLAND; DNA METHYLATION; FEMALE; GENETICS; HUMAN; MALE; MIDDLE AGED; NEUROFIBROMA; NEUROFIBROSARCOMA; POLYMERASE CHAIN REACTION;

ADULT; CENTRAL NERVOUS SYSTEM NEOPLASMS; CPG ISLANDS; DNA METHYLATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROFIBROMA; NEUROFIBROSARCOMA; POLYMERASE CHAIN REACTION;

EID: 0344494159     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.10.5.1519     Document Type: Article

References (34)

1. Woodruff JM, Kourea HP, Louis DN and Scheithauer BW: Neurofibroma. In: Pathology and Genetics. Tumours of the Nervous System. World Health Organization Classification of Tumours. Kleihues P and Cavenee WK (eds). IARC Press, Lyon, pp167-168, 2000.
2. Cawthon RM, Weiss R, Xu G, Viskochil D, Culver M, Stevens J, Robertson M, Dunn D, Gesteland R, O'Connell P and White R: A major segment of the neurofibromatosis type 1 gene: c-DNA sequence, genomic structure, and point mutations. Cell 62: 193-201, 1990.
3. Wallace MR, Marchuk DA, Andersen LB, Letcher R, Odeh HM, Saulino AM, Fountain JW, Brereton A, Nicholson J, Mitchell AL, Brownstein BH and Collins FS: Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 249: 181-186, 1990.
4. Karnes PS: Neurofibromatosis: a common neurocutaneous disorder. Mayo Clin Proc 73: 1071-1076, 1998.
5. Bernards A: Neurofibromatosis type 1 and Ras-mediated signaling: filling in the GAPs. Biochim Biophys Acta 1242: 43-59, 1995.
6. Woodruff JM, Kourea HP, Louis DN and Scheithauer BW: Malignant peripheral nerve sheet tumour (MPNST). In: Pathology and Genetics. Tumours of the Nervous System. World Health Organization Classification of Tumours. Kleihues P and Cavenee WK (eds). IARC Press, Lyon, pp172-174, 2000.
7. Skuse GR, Kosciolek BA and Rowley RT: Molecular genetic analysis of tumours in von Recklinghausen neurofibromatosis. Loss of heterozygosity for chromosome 17. Genes Chromosomes Cancer 1: 36-41, 1989. (Pubitemid 20093337)
8. Rey JA, Bello MJ, Kusak ME, de Campos JM and Pestaña A: Involvement of 22q12 in neurofibrosarcoma in neurofibromatosis type 1. Cancer Genet Cytogenet 66: 28-32, 1993. (Pubitemid 23110243)
9. Koga T, Iwasaki H, Ishiguro M, Matsuzaki A and Kikuchi M: Frequent genomic imbalances in chromosomes 17, 19, and 22q in peripheral nerve sheath tumours detected by comparative genomic hybridization analysis. J Pathol 197: 98-107, 2002. (Pubitemid 34450169)
10. Menon AG, Anderson KM, Riccardi VM, Chung RY, Whaley JM, Yandell DW, Farmer GE, Freiman RN, Lee JK, Li FP, Barker DF, Ledbetter DH, Kleider A, Martuza RL, Gusella JF and Seizinger BR: Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. Proc Natl Acad Sci USA 87: 5435-5439, 1990.
11. Legius E, Dierick H, Wu R, Hall BK, Marynen P, Cassiman JJ and Glover TW: TP53 mutations are frequent in malignant NF1 tumours. Genes Chromosomes Cancer 10: 250-255, 1994. (Pubitemid 24238432)
12. Kourea HP, Orlow I, Scheithauer BW, Cordon-Cardo C and Woodruff JM: Deletions of the INK4A gene occur in malignant peripheral nerve sheath tumours but not in neurofibromas. Am J Pathol 155: 1855-1860, 1999.
13. Nielsen GP, Stemmer-Rachamimov AO, Ino Y, Moller MB, Rosenberg AE and Louis DN: Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. Am J Pathol 155: 1879-1884, 1999.
14. Esteller M and Herman JG: Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol 196: 1-7, 2002.
15. Rey JA, Bello MJ, Jimenez-Lara A, Vaquera J, Kusak ME, de Campos JM, Sarasa JL and Pestaña A: Loss of heterozygosity for distal markers on 22q in human gliomas. Int J Cancer 51: 703-706, 1992.
16. Gonzalez-Gomez P, Bello MJ, Alonso ME, Arjona D, Lomas J, de Campos JM, Isla A and Rey JA: CpG islnad methylation status and mutation analysis of the RB1 gene essential promoter region and protein-binding pocket domain in nervous system tumours. Br J Cancer 88: 109-114, 2003. (Pubitemid 36241226)
17. Gonzalez-Gomez P, Bello MJ, Arjona D, Lomas J, Alonso ME, de Campos JM, Vaquera J, Isla A, Gutierrez M and Rey JA: Promoter hypermethylation of multiple genes in astrocytic gliomas. Int J Oncol 22: 601-608, 2003.
18. Alonso ME, Bello MJ, Gonzalez-Gomez P, Arjona D, Lomas J, de Campos JM, Isla A, Sarasa JL and Rey JA: Aberrant promoter methylation of multiple genes in oligodendrogliomas and ependymomas. Cancer Genet Cytogenet 144: 134-142, 2003. (Pubitemid 36808960)
19. Roberts DD: Regulation of tumour growth and metastasis by thrombospondin-1. FASEB J 10: 1183-1191, 1996.
20. 6-alkylguanine-DNA alkyltransferase regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 50: 6119-6129, 1990.
21. Bachman KE, Herman JG, Corn PG, Merlo A, Costello JF, Cavenee WK, Baylin SB and Graff JR: Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res 59: 798-802, 1999. (Pubitemid 29086729)
22. Nakamura M, Watanabe T, Yonakawa Y, Kleihues P and Ohgaki H: Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C→A:T mutations of the TP53 tumour suppressor gene. Carcinogenesis 22: 1715-1719, 2001. (Pubitemid 32952152)
23. 6-Methylguanine-DNA methyltransferase is associated with the presence of G:A to A:C transition mutations in p53 in human colorectal tumourigenesis. Cancer Res 61: 4689-4692, 2001.
24. Sherr CJ: Cancer cell cycles. Science 274: 1672-1677, 1996.
25. Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF and Sher CJ: Functional and physical interactions of the ARF tumour suppressor with p53 and Mdm2. Proc Natl Acad Sci USA 95: 8292-8297, 1998. (Pubitemid 28326106)
26. INK4a methylation and p53 mutational status. Cancer Res 60: 129-133, 2000.
27. Crybs VL, Thor A, Xu HJ, Hu SX, Wierman ME, Vickery AL, Benedict WF and Arnold A: Loss of retinoblastoma tumour-suppressor gene inparathyroid carcinoma. N Engl J Med 330: 757-761, 1994. (Pubitemid 24080222)
28. Nakamura M, Yonekawa Y, Kleihues P and Ohgaki H: Promoter hypermethylation of the RB1 gene in glioblastomas. Lab Invest 81: 77-82, 2001. (Pubitemid 32108641)
29. Melino G, De Laurenzi V and Vousden KH: P73: friend or foe in tumourigenesis. Nat Rev Cancer 2: 1-11, 2002.
30. Dong S, Pang JC, Hu J, Zhou L and Ng H: Transcriptional inactivation of TP73 expression in oligodendroglial tumours. Int J Cancer 98: 370-375, 2002. (Pubitemid 34188680)
31. Kawano BJ, Miller CW, Gombart AF, Bartram CR, Matsuo Y, Asou H, Sakashita A, Said J, Tatsumi E and Koeffler HP: Loss of p73 gene expression in leukemias/lymphomas due to hypermethylation. Blood 94: 1113-1120, 1999. (Pubitemid 29361845)
32. 6-Methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59: 793-797, 1999.
33. Song JZ, Stirzaker C, Harrison J, Melki JR and Clark SJ: Hypermethylation trigger of glutathione-S-transferase gene (GSTP1) in prostate cancer cells. Oncogene 21: 1048-1061, 2002. (Pubitemid 34174517)
34. Makos M, Nelkin BD, Reiter R, Linehan M, Brooks J, Isaacs W and Baylin SB: Regional DNA hypermethylation at D17S5 precedes 17p structural changes in the progression of renal tumours. Cancer Res 53: 2719-2722, 1993. (Pubitemid 23180503)